期刊文献+

聚乙二醇修饰重组人干扰素-α1b条件的优化 被引量:5

Optimization of Condition for Modification of Recombinant Human Interferon-α1b with Polyethylene Glycol
下载PDF
导出
摘要 目的对聚乙二醇(PEG)衍生物化学修饰重组人干扰素-α1b(rhIFN-α1b)的条件进行优化。方法以3种不同的第2代PEG衍生物对rhIFN-α1b进行修饰,SDS-PAGE分析PEG及修饰产物的表观相对分子质量。对反应pH值、温度、时间、修饰剂用量等修饰条件进行优化,并对修饰产物进行初步分离纯化和活性检测。结果PEG的电泳表观相对分子质量大于其理论值;PEG20000的修饰率(92.1%)高于PEG5000和PEG10000;修饰剂用量和pH值是主要影响因素,最佳pH为9.0,rhIFN-αlb与PEG20000的最佳摩尔比为1∶10,时间和温度影响甚微。单点修饰产物保留了14.4%的体外活性,多点修饰产物无活性。结论选择了合适的PEG衍生物并优化了修饰条件,为进一步深入研究奠定了基础。 Objective To optimize the condition for modification of recombinant human interferon-α1b (rhIFN-α1b) with polyethylene glycol (PEG). Methods Modify rhIFN-α1b with 3 kinds of PEG derivatives of the second generation, determine the apparent relative molecular masses of PEG and the modified rhIFN-α1b, and optimize the condition for modification, such as pH value, temperature, time and dosage of PEG.The modified rhIFN-α1b was primarily separated,purified and determined for activity. Results The apparent relative molecular mass of PEG was higher than that in theory. The modification rate of rhIFN-α1b with PEG20000(92.1% ) were significantly higher than that with PEG5000 or with PEG10000. The dosage of PEG and pH value showed significant influence, while time and temperature showed little influence on the modi- fication effect.The optimal pH value for modification was 9.0,and the optimal molar ratio of rhIFN-α1b to rhIFN-α1b to PEG20000 was 1 : 10.The mono-pegylated rhIFN-α1b reserved 14.4% of activity in vitro,while poly-pegylated rhIFN-α1b showed no activity. Conclusion The optimal PEG derivative for modification of rhIFN-α1b was screened,and the condition for modification was optimized, which laid a foundation of further study on modification of interferon with PEG.
出处 《中国生物制品学杂志》 CAS CSCD 2008年第4期329-332,共4页 Chinese Journal of Biologicals
基金 国家863计划专题课题(2007AA02Z100) 上海市科委重点攻关计划(054319924)
关键词 聚乙二醇 重组人干扰素-α1b 化学修饰 优化 Polyethylene glycol Recombinant human interferon-α1b Chemical modification Optimization
  • 相关文献

参考文献7

  • 1Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov,2003,2(3) :214-212.
  • 2Kurfurst MM. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem, 1992,200(2) :244-248.
  • 3Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylaled interferons for treatment of hepatitis C. J Control Release, 2001,72 ( 1- 3):217-224.
  • 4Caliceti P. Pharmacokinefics of pegylated inteferons: what is misleading. Dig Liver Dis, 2004,36 ( suppl 3 ) : S334-S339.
  • 5Na DH, Park EJ, Youn YS, et al. Sodium dodecyl sulfate-capillary gel electrophoresis of polyethylene glycolylated interferon alpha. Electrophoresis, 2004,25 (3) : 476-479.
  • 6Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev, 2003, 55(10) : 1261-1277.
  • 7Malik F, Delgado C, Knüsli C, et al. Polyethylene glycol (PEG)-modified granulocyte- macrophage colony-stimulating factor (GM-CSF) with conserved biological activity. Exp Hematol, 1992,20(8) : 1028-1035.

同被引文献60

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部